Report Summary
Biosimilars and Biologics-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Biosimilars and Biologics industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Biosimilars and Biologics 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Biosimilars and Biologics worldwide and market share by regions, with company and product introduction, position in the Biosimilars and Biologics market
Market status and development trend of Biosimilars and Biologics by types and applications
Cost and profit status of Biosimilars and Biologics, and marketing status
Market growth drivers and challenges
The report segments the global Biosimilars and Biologics market as:
Global Biosimilars and Biologics Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Biosimilars and Biologics Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody
Hormone
Growth Factors
Other
Global Biosimilars and Biologics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Global Biosimilars and Biologics Market: Manufacturers Segment Analysis (Company and Product introduction, Biosimilars and Biologics Sales Volume, Revenue, Price and Gross Margin):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Teva Pharmaceutical
MYLAN
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Frequently Asked Questions
These dominant industry players use well planned strategies to occupied highest market share in this market. Some of the top players in [Keyword] business includes.
[Company list]
As per [Keyword] market analysis, North America is forecasted to occupied major share in the [Keyword] market.
The statistical data of the dominant industry player of [Keyword] market can be acquired from the company profile segment described in the report. This segment come up with analysis of major player’s in the [Keyword] market, also their last five-year revenue, segmental, product offerings, key strategies adopted and geographical revenue produced.
The report come up with a segment of the [Keyword] market based on Type, Region, and Application, Also offer a determined view on the [Keyword] market.
The report offers a nitty-gritty estimation of the market by providing data on various viewpoints that incorporate, restraints, drivers, and opportunities threats. This data can help in making suitable decisions for stakeholders before investing.
The sample report for [Keyword] market can be received after the apply from the website.
Table Of Content
Table of Contents
Chapter 1 Overview of Biosimilars and Biologics
1.1 Definition of Biosimilars and Biologics in This Report
1.2 Commercial Types of Biosimilars and Biologics
1.2.1 Antibody
1.2.2 Hormone
1.2.3 Growth Factors
1.2.4 Other
1.3 Downstream Application of Biosimilars and Biologics
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biosimilars and Biologics
1.5 Market Status and Trend of Biosimilars and Biologics 2013-2023
1.5.1 Global Biosimilars and Biologics Market Status and Trend 2013-2023
1.5.2 Regional Biosimilars and Biologics Market Status and Trend 2013-2023
Chapter 2 Global Market Status and Forecast by Regions
2.1 Market Development of Biosimilars and Biologics 2013-2017
2.2 Sales Market of Biosimilars and Biologics by Regions
2.2.1 Sales Volume of Biosimilars and Biologics by Regions
2.2.2 Sales Value of Biosimilars and Biologics by Regions
2.3 Production Market of Biosimilars and Biologics by Regions
2.4 Global Market Forecast of Biosimilars and Biologics 2018-2023
2.4.1 Global Market Forecast of Biosimilars and Biologics 2018-2023
2.4.2 Market Forecast of Biosimilars and Biologics by Regions 2018-2023
Chapter 3 Global Market Status and Forecast by Types
3.1 Sales Volume of Biosimilars and Biologics by Types
3.2 Sales Value of Biosimilars and Biologics by Types
3.3 Market Forecast of Biosimilars and Biologics by Types
Chapter 4 Global Market Status and Forecast by Downstream Industry
4.1 Global Sales Volume of Biosimilars and Biologics by Downstream Industry
4.2 Global Market Forecast of Biosimilars and Biologics by Downstream Industry
Chapter 5 North America Market Status by Countries, Type, Manufacturers and Downstream Industry
5.1 North America Biosimilars and Biologics Market Status by Countries
5.1.1 North America Biosimilars and Biologics Sales by Countries (2013-2017)
5.1.2 North America Biosimilars and Biologics Revenue by Countries (2013-2017)
5.1.3 United States Biosimilars and Biologics Market Status (2013-2017)
5.1.4 Canada Biosimilars and Biologics Market Status (2013-2017)
5.1.5 Mexico Biosimilars and Biologics Market Status (2013-2017)
5.2 North America Biosimilars and Biologics Market Status by Manufacturers
5.3 North America Biosimilars and Biologics Market Status by Type (2013-2017)
5.3.1 North America Biosimilars and Biologics Sales by Type (2013-2017)
5.3.2 North America Biosimilars and Biologics Revenue by Type (2013-2017)
5.4 North America Biosimilars and Biologics Market Status by Downstream Industry (2013-2017)
Chapter 6 Europe Market Status by Countries, Type, Manufacturers and Downstream Industry
6.1 Europe Biosimilars and Biologics Market Status by Countries
6.1.1 Europe Biosimilars and Biologics Sales by Countries (2013-2017)
6.1.2 Europe Biosimilars and Biologics Revenue by Countries (2013-2017)
6.1.3 Germany Biosimilars and Biologics Market Status (2013-2017)
6.1.4 UK Biosimilars and Biologics Market Status (2013-2017)
6.1.5 France Biosimilars and Biologics Market Status (2013-2017)
6.1.6 Italy Biosimilars and Biologics Market Status (2013-2017)
6.1.7 Russia Biosimilars and Biologics Market Status (2013-2017)
6.1.8 Spain Biosimilars and Biologics Market Status (2013-2017)
6.1.9 Benelux Biosimilars and Biologics Market Status (2013-2017)
6.2 Europe Biosimilars and Biologics Market Status by Manufacturers
6.3 Europe Biosimilars and Biologics Market Status by Type (2013-2017)
6.3.1 Europe Biosimilars and Biologics Sales by Type (2013-2017)
6.3.2 Europe Biosimilars and Biologics Revenue by Type (2013-2017)
6.4 Europe Biosimilars and Biologics Market Status by Downstream Industry (2013-2017)
Chapter 7 Asia Pacific Market Status by Countries, Type, Manufacturers and Downstream Industry
7.1 Asia Pacific Biosimilars and Biologics Market Status by Countries
7.1.1 Asia Pacific Biosimilars and Biologics Sales by Countries (2013-2017)
7.1.2 Asia Pacific Biosimilars and Biologics Revenue by Countries (2013-2017)
7.1.3 China Biosimilars and Biologics Market Status (2013-2017)
7.1.4 Japan Biosimilars and Biologics Market Status (2013-2017)
7.1.5 India Biosimilars and Biologics Market Status (2013-2017)
7.1.6 Southeast Asia Biosimilars and Biologics Market Status (2013-2017)
7.1.7 Australia Biosimilars and Biologics Market Status (2013-2017)
7.2 Asia Pacific Biosimilars and Biologics Market Status by Manufacturers
7.3 Asia Pacific Biosimilars and Biologics Market Status by Type (2013-2017)
7.3.1 Asia Pacific Biosimilars and Biologics Sales by Type (2013-2017)
7.3.2 Asia Pacific Biosimilars and Biologics Revenue by Type (2013-2017)
7.4 Asia Pacific Biosimilars and Biologics Market Status by Downstream Industry (2013-2017)
Chapter 8 Latin America Market Status by Countries, Type, Manufacturers and Downstream Industry
8.1 Latin America Biosimilars and Biologics Market Status by Countries
8.1.1 Latin America Biosimilars and Biologics Sales by Countries (2013-2017)
8.1.2 Latin America Biosimilars and Biologics Revenue by Countries (2013-2017)
8.1.3 Brazil Biosimilars and Biologics Market Status (2013-2017)
8.1.4 Argentina Biosimilars and Biologics Market Status (2013-2017)
8.1.5 Colombia Biosimilars and Biologics Market Status (2013-2017)
8.2 Latin America Biosimilars and Biologics Market Status by Manufacturers
8.3 Latin America Biosimilars and Biologics Market Status by Type (2013-2017)
8.3.1 Latin America Biosimilars and Biologics Sales by Type (2013-2017)
8.3.2 Latin America Biosimilars and Biologics Revenue by Type (2013-2017)
8.4 Latin America Biosimilars and Biologics Market Status by Downstream Industry (2013-2017)
Chapter 9 Middle East and Africa Market Status by Countries, Type, Manufacturers and Downstream Industry
9.1 Middle East and Africa Biosimilars and Biologics Market Status by Countries
9.1.1 Middle East and Africa Biosimilars and Biologics Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Biosimilars and Biologics Revenue by Countries (2013-2017)
9.1.3 Middle East Biosimilars and Biologics Market Status (2013-2017)
9.1.4 Africa Biosimilars and Biologics Market Status (2013-2017)
9.2 Middle East and Africa Biosimilars and Biologics Market Status by Manufacturers
9.3 Middle East and Africa Biosimilars and Biologics Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Biosimilars and Biologics Sales by Type (2013-2017)
9.3.2 Middle East and Africa Biosimilars and Biologics Revenue by Type (2013-2017)
9.4 Middle East and Africa Biosimilars and Biologics Market Status by Downstream Industry (2013-2017)
Chapter 10 Market Driving Factor Analysis of Biosimilars and Biologics
10.1 Global Economy Situation and Trend Overview
10.2 Biosimilars and Biologics Downstream Industry Situation and Trend Overview
Chapter 11 Biosimilars and Biologics Market Competition Status by Major Manufacturers
11.1 Production Volume of Biosimilars and Biologics by Major Manufacturers
11.2 Production Value of Biosimilars and Biologics by Major Manufacturers
11.3 Basic Information of Biosimilars and Biologics by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Biosimilars and Biologics Major Manufacturer
11.3.2 Employees and Revenue Level of Biosimilars and Biologics Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
Chapter 12 Biosimilars and Biologics Major Manufacturers Introduction and Market Data
12.1 Roche
12.1.1 Company profile
12.1.2 Representative Biosimilars and Biologics Product
12.1.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Roche
12.2 Amgen
12.2.1 Company profile
12.2.2 Representative Biosimilars and Biologics Product
12.2.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Amgen
12.3 AbbVie
12.3.1 Company profile
12.3.2 Representative Biosimilars and Biologics Product
12.3.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of AbbVie
12.4 Sanofi-Aventis
12.4.1 Company profile
12.4.2 Representative Biosimilars and Biologics Product
12.4.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
12.5 Johnson & Johnson
12.5.1 Company profile
12.5.2 Representative Biosimilars and Biologics Product
12.5.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.6 Pfizer
12.6.1 Company profile
12.6.2 Representative Biosimilars and Biologics Product
12.6.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Pfizer
12.7 Novo Nordisk
12.7.1 Company profile
12.7.2 Representative Biosimilars and Biologics Product
12.7.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.8 Eli Lilly
12.8.1 Company profile
12.8.2 Representative Biosimilars and Biologics Product
12.8.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Eli Lilly
12.9 Novartis
12.9.1 Company profile
12.9.2 Representative Biosimilars and Biologics Product
12.9.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Novartis
12.10 Merck
12.10.1 Company profile
12.10.2 Representative Biosimilars and Biologics Product
12.10.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Merck
12.11 Sun
12.11.1 Company profile
12.11.2 Representative Biosimilars and Biologics Product
12.11.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Sun
12.12 3sbio
12.12.1 Company profile
12.12.2 Representative Biosimilars and Biologics Product
12.12.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of 3sbio
12.13 Changchun High Tech
12.13.1 Company profile
12.13.2 Representative Biosimilars and Biologics Product
12.13.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Changchun High Tech
12.14 CP Guojian
12.14.1 Company profile
12.14.2 Representative Biosimilars and Biologics Product
12.14.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of CP Guojian
12.15 Biotech
12.15.1 Company profile
12.15.2 Representative Biosimilars and Biologics Product
12.15.3 Biosimilars and Biologics Sales, Revenue, Price and Gross Margin of Biotech
12.16 Gelgen
12.17 Innovent
12.18 Dong Bao
12.19 Ganlee
12.20 United Laboratories
12.21 Teva Pharmaceutical
12.22 MYLAN
Chapter 13 Upstream and Downstream Market Analysis of Biosimilars and Biologics
13.1 Industry Chain of Biosimilars and Biologics
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
Chapter 14 Cost and Gross Margin Analysis of Biosimilars and Biologics
14.1 Cost Structure Analysis of Biosimilars and Biologics
14.2 Raw Materials Cost Analysis of Biosimilars and Biologics
14.3 Labor Cost Analysis of Biosimilars and Biologics
14.4 Manufacturing Expenses Analysis of Biosimilars and Biologics
Chapter 15 Report Conclusion
Chapter 16 Research Methodology and Reference
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
Inquiry For Buying
Biosimilars and Biologics
Please fill out the form. We will contact you within 24 hours:
All fields required...
Request Sample
Biosimilars and Biologics
Please fill out the form. We will contact you within 24 hours:
All fields required...
